Suppr超能文献

慢性肾脏病3至5期的骨脆性:维生素D补充剂的应用

Bone Fragility in Chronic Kidney Disease Stage 3 to 5: The Use of Vitamin D Supplementation.

作者信息

Ureña Torres Pablo Antonio, Souberbielle Jean Claude, Solal Martine Cohen

机构信息

Department of Dialysis AURA Nord Saint Ouen, 12, Rue Anselme, 93400 Saint Ouen, France.

Department of Renal Physiology, Necker Hospital, University of Paris Descartes, 75015 Paris, France.

出版信息

Metabolites. 2022 Mar 20;12(3):266. doi: 10.3390/metabo12030266.

Abstract

Frequently silent until advanced stages, bone fragility associated with chronic kidney disease-mineral and bone disease (CKD-MBD) is one of the most devastating complications of CKD. Its pathophysiology includes the reduction of active vitamin D metabolites, phosphate accumulation, decreased intestinal calcium absorption, renal alpha klotho production, and elevated fibroblast growth factor 23 (FGF23) levels. Altogether, these factors contribute firstly to secondary hyperparathyroidism, and ultimately, to micro- and macrostructural bone changes, which lead to low bone mineral density and an increased risk of fracture. A vitamin D deficiency is common in CKD patients, and low circulating 25(OH)D levels are invariably associated with high serum parathyroid hormone (PTH) levels as well as with bone mineralization defects, such as osteomalacia in case of severe forms. It is also associated with a variety of non-skeletal diseases, including cardiovascular disease, diabetes mellitus, multiple sclerosis, cancer, and reduced immunological response. Current international guidelines recommend supplementing CKD patients with nutritional vitamin D as in the general population; however, there is no randomized clinical trial (RCT) evaluating the effect of vitamin D (or vitamin D+calcium) supplementation on the risk of fracture in the setting of CKD. It is also unknown what level of circulating 25(OH)D would be sufficient to prevent bone abnormalities and fractures in these patients. The impact of vitamin D supplementation on other surrogate endpoints, including bone mineral density and bone-related circulating biomarkers (PTH, FGF23, bone-specific alkaline phosphatase, sclerostin) has been evaluated in several RTCs; however, the results were not always translated into an improvement in long-term outcomes, such as reduced fracture risk. This review provides a brief and comprehensive update on CKD-related bone fragility and the use of natural vitamin D supplementation in these patients.

摘要

与慢性肾脏病 - 矿物质和骨异常(CKD - MBD)相关的骨脆性在疾病晚期之前常常没有症状,是CKD最具破坏性的并发症之一。其病理生理学包括活性维生素D代谢产物减少、磷酸盐蓄积、肠道钙吸收减少、肾脏α - klotho生成减少以及成纤维细胞生长因子23(FGF23)水平升高。总之,这些因素首先导致继发性甲状旁腺功能亢进,最终导致骨骼微观和宏观结构改变,进而导致骨矿物质密度降低和骨折风险增加。维生素D缺乏在CKD患者中很常见,循环中25(OH)D水平低总是与高血清甲状旁腺激素(PTH)水平以及骨矿化缺陷相关,严重时会出现骨软化症。它还与多种非骨骼疾病有关,包括心血管疾病、糖尿病、多发性硬化症、癌症以及免疫反应降低。目前的国际指南建议像普通人群一样给CKD患者补充营养性维生素D;然而,尚无随机临床试验(RCT)评估维生素D(或维生素D + 钙)补充对CKD患者骨折风险的影响。也不清楚循环中25(OH)D达到何种水平足以预防这些患者的骨骼异常和骨折。在一些RTC中评估了维生素D补充对其他替代终点的影响,包括骨矿物质密度和骨相关循环生物标志物(PTH、FGF23、骨特异性碱性磷酸酶、硬化蛋白);然而,结果并不总是能转化为长期结局的改善,如降低骨折风险。本综述简要全面地更新了与CKD相关的骨脆性以及这些患者使用天然维生素D补充剂的情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7884/8953916/40e591748010/metabolites-12-00266-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验